Table 1.
Characteristic | Statistic |
---|---|
No. patients | 18 |
Age, years | 57 [43-75] |
Female | 10 (56) |
KPS | 80 [50-90] |
NFS | 1 [0-3] |
Prior smoker | 8 (44) |
Comorbid disease | |
Body mass index | 27 ± 5 |
Hypertension | 9 (50) |
Hyperlipidemia | 4 (22) |
Diabetes | 2 (11) |
Extent of spinal disease | |
Single level | 4 (22) |
Multilevel (2-5 VB) | 11 (61) |
Diffuse | 3 (17) |
Visceral metastasesb | 10 (56) |
Brain metastases | 1 (16) |
Extraspinal bony metastases | 9 (50) |
Concurrent medical therapies | |
Concurrent steroids | 4 (22) |
Chemotherapy | 2 (11) |
Bisphosphonates | 2 (11) |
No. prior chemotherapy regimens | 0 [0-5] |
Histology | |
Leiomyosarcoma | 6 (32) |
Chondrosarcoma | 3 (17) |
Spindle cell | 3 (17) |
Pleomorphic | 2 (11) |
Liposarcoma | 2 (11) |
Osteosarcoma | 1 (6) |
Myxofibrosarcoma | 1 (6) |
Abbreviations: KPS, Karnofsky Performance Status; NFS, neurologic function scale; No., number; VB, vertebral bodies.
aValues are presented as mean ± standard deviation, number (percentage), or median [range].
bOrgan metastases other than bone or brain.